Back to results
US 2020/0345664 A1Published application
Dosage forms and methods for enantiomerically enriched or pure bupropion
AssigneeAxsome Therapeutics, Inc.
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.
Claims20
A method of treating a condition, comprising:
- selecting a human being having the condition, wherein the condition is treated by achieving a first AUC0-24 of bupropion, wherein the first AUC0-24 of bupropion is the same as a reference AUC0-24 of bupropion that results from orally administering a daily dose of racemic bupropion, wherein the daily dose of racemic bupropion is about 250 mg to about 300 mg;
- and
- orally administering a daily dose of an (S)-bupropion to the human being to achieve the first AUC0-24 of bupropion, wherein the daily dose of the (S)-bupropion is about 100 mg to about 180 mg;
- wherein the (S)-bupropion is at least 95% enantiomerically pure, and no other bupropion is orally administered with the daily dose of the (S)-bupropion;
- and
- wherein the daily dose of the (S)-bupropion is about 40% to about 60% of the daily dose of racemic bupropion.
3 more elements
Dependencies are inferred from the claim text.